Controlled Study of Haloperidol, Pimozide, and Placebo for the Treatment of Gilles de la Tourette's Syndrome

Elaine Shapiro, Arthur K. Shapiro, George Fulop, Michael Hubbard, John Mandeli, Johanna Nordlie, Robert A. Phillips

Research output: Contribution to journalArticlepeer-review

325 Scopus citations

Abstract

The results of this controlled study of the treatment of 57 patients with Gilles de la Tourette's syndrome suggested that both haloperidol and pimozide were more effective than placebo, but that haloperidol was slightly more effective than pimozide. Adverse effects occurred more frequently with haloperidol vs placebo than with pimozide vs placebo, but the frequency was not significantly different for haloperidol compared with pimozide. Clinically significant cardiac effects did not occur at a maximum dosage of 0.3 mg/kg or 20 mg/d for pimozide and 10 mg/d for haloperidol. However, the QTc interval was prolonged during pimozide treatment compared with that during haloperidol treatment, although the values for both medications were not in an abnormal range.

Original languageEnglish (US)
Pages (from-to)722-730
Number of pages9
JournalArchives of General Psychiatry
Volume46
Issue number8
DOIs
StatePublished - 1989

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Controlled Study of Haloperidol, Pimozide, and Placebo for the Treatment of Gilles de la Tourette's Syndrome'. Together they form a unique fingerprint.

Cite this